Pifusertib

DB15054InvestigationalSmall molecule

TAS-117 is under investigation in clinical trial NCT03017521 (K-BASKET, TAS-117, PI3K/AKT Gene Aberration).

Mechanism: Pharmacologically active on RAC-alpha serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-gamma serine/threonine-protein kinase
Curator reviewed
Formula / weight: C₂₆H₂₄N₄O₂ · 424.504 g/mol (avg)
Code names: TAS-117

Resolves to

Compound

Structure

InChIKeyAIFGVDXMHWGOGJ-DIVCQZSQSA-NSMILESC[C@@]1(O)C[C@@](N)(C1)C1=CC=C(C=C1)C1=C(N2COC3=CC=NC=C3C2=N1)C1=CC=CC=C1

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pifusertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.